Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

by Zacks Equity Research

Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.

Zacks Equity Research

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

by Zacks Equity Research

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.

Zacks Equity Research

Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sweta Killa headshot

5 Stocks Propelling S&P 500 to 25th Record High

by Sweta Killa

The S&P 500 touches a record high for the 25th time this year, powered by technology stocks. We have highlighted five technology stocks, HPE, MRNA, AVGO, MU and LRCX, leading the way higher in the latest trading session.

Zacks Equity Research

Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQEW

Sundeep Ganoria headshot

FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains

by Sundeep Ganoria

An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.

Zacks Equity Research

Company News for June 4, 2024

by Zacks Equity Research

Companies In The Article Are:NVDA, MRK,MRNA, SPOT, SRCL and WM

Zacks Equity Research

Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine

by Zacks Equity Research

The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.

Zacks Equity Research

The Zacks Analyst Blog Highlights NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm

by Zacks Equity Research

NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm are part of the Zacks top Analyst Blog.